These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25659187)

  • 1. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
    Heo JY; Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; Pisoni A; Papakostas GI
    J Psychiatr Res; 2015 Mar; 62():56-61. PubMed ID: 25659187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.
    Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; DiPierro M; Cardoos A; Papakostas GI
    Int Clin Psychopharmacol; 2014 Nov; 29(6):332-8. PubMed ID: 24815673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
    Papakostas GI; Vitolo OV; Ishak WW; Rapaport MH; Zajecka JM; Kinrys G; Mischoulon D; Lipkin SH; Hails KA; Abrams J; Ward SG; Meisner A; Schoenfeld DA; Shelton RC; Winokur A; Okasha MS; Bari MA; Fava M
    J Clin Psychiatry; 2012 Dec; 73(12):1541-7. PubMed ID: 23290327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone augmentation for anxious depression.
    Ionescu DF; Shelton RC; Baer L; Meade KH; Swee MB; Fava M; Papakostas GI
    Int Clin Psychopharmacol; 2016 Nov; 31(6):341-6. PubMed ID: 27306192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
    Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
    J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
    J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study.
    Lohoff FW; Etemad B; Mandos LA; Gallop R; Rickels K
    J Clin Psychopharmacol; 2010 Apr; 30(2):185-9. PubMed ID: 20520293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
    Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
    Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.
    Patkar AA; Pae CU; Vöhringer PA; Mauer S; Narasimhan M; Dalley S; Loebel A; Masand PS; Ghaemi SN
    J Clin Psychopharmacol; 2015 Jun; 35(3):319-23. PubMed ID: 25882763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project.
    Wiethoff K; Bauer M; Baghai TC; Möller HJ; Fisher R; Hollinde D; Kiermeir J; Hauth I; Laux G; Cordes J; Brieger P; Kronmüller KT; Zeiler J; Adli M
    J Clin Psychiatry; 2010 Aug; 71(8):1047-54. PubMed ID: 20673545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.